<DOC>
	<DOC>NCT00999063</DOC>
	<brief_summary>This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.</brief_summary>
	<brief_title>Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures Female or male aged at least 18 years Patient must be having symptoms suggestive of upper gastrointestinal tract symptoms such as heart burn/ regurgitation Involvement in the planning and /or conduct of the study (applies to both AstraZeneca staff and /or staff at study site Participation in a clinical study(excluding noninterventional study or registry) during the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>GerdQ</keyword>
</DOC>